The present invention is concerned with novel isoxazoles of formula I
wherein X, R
1
, R
2
, R
3
and R
4
are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A α5 receptor. Further the present invention is concerned with the manufacture of the active compounds of formula I, pharmaceutical compositions containing them and their use as therapeutics.
本发明涉及公式I的新型异噁唑,其中X,R1,R2,R3和R4如本文所述,以及其药学上可接受的盐和酯。本发明的活性化合物具有对GABA A α5受体的亲和力和选择性。此外,本发明还涉及制造公式I的活性化合物,含有它们的药物组合物以及它们作为治疗药物的用途。
Pyridines
申请人:Buettelmann Bernd
公开号:US08357703B2
公开(公告)日:2013-01-22
The present invention is concerned with novel isoxazoles of formula I
wherein X, R1, R2, R3 and R4 are as described herein, as well as pharmaceutically acceptable salts and esters thereof. The active compounds of the present invention have affinity and selectivity for GABA A α5 receptor. Further the present invention is concerned with the manufacture of the active compounds of formula I, pharmaceutical compositions containing them and their use as therapeutics.
本发明涉及公式I的新型异恶唑,其中X,R1,R2,R3和R4如本文所述,以及其药学上可接受的盐和酯。本发明的活性化合物对GABA A α5受体具有亲和力和选择性。此外,本发明涉及制备公式I的活性化合物,包含它们的制药组合物以及它们作为治疗剂的用途。
ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS
申请人:F.Hoffmann-La Roche AG
公开号:EP2427457A1
公开(公告)日:2012-03-14
CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 RECEPTOR ANTAGONISTIC EFFECT
申请人:Shionogi & Co., Ltd.
公开号:US20210040117A1
公开(公告)日:2021-02-11
Novel compounds having a D3 receptor antagonistic effect are provided.
The compound represented by Formula (IA)′:
wherein A is S or O; R
1a
is substituted or unsubstituted alkyloxy or the like, R
2a
to R
2d
are each independently hydrogen atoms or the like, ring B is a 4- to 8-membered non-aromatic carbocycle or the like, R
3
is each independently halogen or the like, r is an integer of 0 to 4, R
4
is substituted or unsubstituted aromatic heterocyclyl or the like,
or a pharmaceutically acceptable salt thereof.